Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. 1993

D L Persons, and L C Hartmann, and J F Herath, and T J Borell, and W A Cliby, and G L Keeney, and R B Jenkins
Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota.

Karyotype information on ovarian carcinomas has been limited because the tumors are often difficult to culture and the resultant metaphases can have complex numerical and structural chromosomal anomalies. Fluorescent in situ hybridization is a rapid method of determining centromere copy number in metaphase cells and interphase nuclei. Fluorescent in situ hybridization was used to determine the numerical centromere complement of chromosomes X, 8, 12, and 17 and HER-2/neu gene amplification within interphase nuclei of 25 primary epithelial ovarian carcinomas. Touch preparations of the carcinomas were hybridized with two-color combinations of directly labeled alpha-satellite centromeric chromosome enumeration probes and a directly labeled HER-2/neu probe. Modal centromere copy numbers for each of the four chromosomes were used to determine numerical abnormalities relative to the flow cytometric DNA ploidy level for each tumor. Four cases were found to be normal with respect to the four chromosomes studied. In the remaining 21 cases a relative loss of chromosomes 17 (16 cases) and X (nine cases) and a relative gain of chromosomes 12 (10 cases) and 8 (nine cases) were the most common findings. In addition, the HER-2/neu gene was amplified in two of the 25 tumors. In conclusion, fluorescent in situ hybridization is an excellent method for rapid determination of numerical abnormalities and gene amplification in ovarian carcinomas.

UI MeSH Term Description Entries
D007399 Interphase The interval between two successive CELL DIVISIONS during which the CHROMOSOMES are not individually distinguishable. It is composed of the G phases (G1 PHASE; G0 PHASE; G2 PHASE) and S PHASE (when DNA replication occurs). Interphases
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011003 Ploidies The degree of replication of the chromosome set in the karyotype. Ploidy
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002503 Centromere The clear constricted portion of the chromosome at which the chromatids are joined and by which the chromosome is attached to the spindle during cell division. Centromeres
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene

Related Publications

D L Persons, and L C Hartmann, and J F Herath, and T J Borell, and W A Cliby, and G L Keeney, and R B Jenkins
May 1997, Laboratory investigation; a journal of technical methods and pathology,
D L Persons, and L C Hartmann, and J F Herath, and T J Borell, and W A Cliby, and G L Keeney, and R B Jenkins
October 1996, Laboratory investigation; a journal of technical methods and pathology,
D L Persons, and L C Hartmann, and J F Herath, and T J Borell, and W A Cliby, and G L Keeney, and R B Jenkins
August 1994, Cancer research,
D L Persons, and L C Hartmann, and J F Herath, and T J Borell, and W A Cliby, and G L Keeney, and R B Jenkins
January 1992, Clinical neurology and neurosurgery,
D L Persons, and L C Hartmann, and J F Herath, and T J Borell, and W A Cliby, and G L Keeney, and R B Jenkins
January 2011, Cancer,
D L Persons, and L C Hartmann, and J F Herath, and T J Borell, and W A Cliby, and G L Keeney, and R B Jenkins
January 2008, Asian Pacific journal of cancer prevention : APJCP,
D L Persons, and L C Hartmann, and J F Herath, and T J Borell, and W A Cliby, and G L Keeney, and R B Jenkins
February 1998, The American journal of pathology,
D L Persons, and L C Hartmann, and J F Herath, and T J Borell, and W A Cliby, and G L Keeney, and R B Jenkins
January 1992, Clinical and laboratory haematology,
D L Persons, and L C Hartmann, and J F Herath, and T J Borell, and W A Cliby, and G L Keeney, and R B Jenkins
January 1995, Cancer detection and prevention,
D L Persons, and L C Hartmann, and J F Herath, and T J Borell, and W A Cliby, and G L Keeney, and R B Jenkins
March 1996, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!